Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 10/20 | 0.38 |
| ▸ | NPC1 | O15118 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.36 |
| ▸ | RELA | Q04206 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243349 | 0.75 | SMPD3 (0.51) | L3MBTL1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL460099 | 0.73 | L3MBTL1 (0.37) | L3MBTL1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2364454 | 0.70 | L3MBTL1 (0.37) | L3MBTL1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11437620 | 0.69 | HTT (0.37) | L3MBTL1TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL20045386 | 0.67 | TDP1 (0.43) | L3MBTL1TDP1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL10954801 | 0.67 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTATM | |
| SCHEMBL23709740 | 0.66 | TDP1 (0.42) | L3MBTL1TDP1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL11319517 | 0.65 | L3MBTL1 (0.41) | L3MBTL1TDP1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL25653941 | 0.65 | L3MBTL1 (0.41) | L3MBTL1TDP1RAB9ANPC1ATM | |
| SCHEMBL2484623 | 0.65 | TLR7 (0.38) | L3MBTL1TDP1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544988-B1 | Pyrazolo(1,5-a)pyrimidin-6-yl)-1H-pyridin-2-one derivatives | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1161433-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380203-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; TREATMENT OF TYROSINE KINASE-DEPENDENT DISEASES/CONDITIONS SUCH AS ANGIOGENESIS, CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY OR AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| EP-1161433-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| US-6235741-B1 | ANTICANCER AGENTS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0984692-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-2000053605-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| EP-0984692-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054093-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | L3MBTL1 4083/4885TDP1 3046/4885RAB9A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.